Trials / Completed
CompletedNCT04882644
Effects of Aerobic Exercise on Lean Non-alcoholic Fatty Liver Disease (NAFLD)
Effects of Aerobic Exercise on Lean Non-alcoholic Fatty Liver Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 30 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
NAFLD is increasingly being identified in lean individuals, especially in Chinese population. Among the NAFLD patients, the lean NAFLD accounts for 15.9%-23.0%. Previous studies showed that the lean NAFLD individuals might have a higher risk of severe hepatic disease than those obese individuals. However, the effects of aerobic exercise on the reduction of liver fat content and metabolic risk factors in lean NAFLD individuals remain unknown. In this randomized controlled trial, we will examine the effect of a 3-month exercise training (aerobic exercise) on liver fat content and metabolic risk factors in lean NAFLD individuals.
Detailed description
The whole study is divided into four phases: recruitment phase, training phase (1 month, aim to gradually adapt patients to the target exercise intensity), implementation phase (3 months), and follow-up phase (9 months). And the subjects are randomly assigned to two groups: aerobic exercise intervention group and control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Aerobic Exercise | The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months. |
Timeline
- Start date
- 2021-05-14
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2021-05-12
- Last updated
- 2024-09-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04882644. Inclusion in this directory is not an endorsement.